CIMR-Wei Shao

Core Facilitiy Director

Wei Shao

Songbiao Zhu

Research Group

Wei Shao

shaowei(at)cimrbj.ac.cn

Director of High-Throughput Screening Facility

shaowei(at)cimrbj.ac.cn

Ph.D. Tsinghua University, China

M.A. in botany, Lanzhou University, China

B.S. in Biological Sciences, Lanzhou University, China

Work Experience

2024.04-present

Director, High-Throughput Screening Facility, CIMR, Beijing, China

2021.04-2024.03

Project director, Iomics Biosciences Inc., Beijing, China

2018.09-2021.04

Senior Scientist, Global Health Drug Discovery Institute, Beijing, China

2008.08-2013.07

Engineer, National Institute of Biological Sciences, Beijing, China

Introduction

The High Throughput Screening Facility (HTSF) is a technical assistance platform of the Chinese Institutes for Medical Research (CIMR), situated on the underground floor of the South Building of the Basic Research Building, Capital Medical University. The platform will establish various types of compound libraries, including FDA-approved or clinical compounds, known active libraries, structurally diverse libraries, natural product libraries, and disease/target related libraries. Additionally, HTSF will be equipped with advanced fully automated high-throughput screening equipment to support the development and optimization of multiple biochemical or cell-based screening models covering various detection types such as fluorescence, Alpha Screen, luminescence, absorbance, and image-based screening. The High Throughput Screening Facility aims to provide excellent screening services, promote drug discovery through efficient processes and high-quality data, and support both internal and external project collaborations.

Representative Publications *：Co-first author; #：Co-corresponding author

Shao W^*, Li SS^*, Li L, Lin KQ, Liu XH, Wang HY, Wang HL, Wang D^#. Chemical genomics reveals inhibition of breast cancer lung metastasis by Ponatinib via c-Jun. Protein & Cell, 2019, 10: 161-177. DOI: 10.1007/s13238-018-0533-8

Wang YM^*, Wang HY^*, Shao W, Chen YH, Gui Y, Hu C, Yi XH, Huang LJ, Li SS^#, Wang D^#. Large-scale loss-of-function perturbations reveal a comprehensive epigenetic regulatory network in breast cancer. Cancer Biology & Medicine, 2023, 21: 83-103. DOI: 10.20892/j.issn.2095-3941.2023.0276

Wang QY, Li SS, Dai YF, Yu XK, Wang YM, Li L, Yang M, Lin KQ, Shao W, Wang HY, Wang HL, Zhang GB^#, Wang D^#. Reversing myeloid-derived suppressor cells mediated immunosuppression via p38α inhibition enhances immunotherapy efficacy in triple negative breast cancer. BioRxiv, 2023. DOI: 10.1101/2023.03.31.535102

Yang YQ^#*, Liu XH^*, Guo W, Liu W, Shao W, Zhao J, Li JH, Dong Q, Ma L, He Q, Li YZ, Han JY, Lei XG^#. Testing the polar auxin transport model with a selective plasma membrane H+/-ATPase inhibitor. Journal of Integrative Plant Biology, 2022, 64: 1229-1245. DOI: 10.1111/jipb.13256

Wang HY^*, Li SS^*, Wang QY^*, Jin ZS, Shao W, Gao Y, Li L, Lin KQ, Zhu L, Wang HL, Liao XB, Wang D#. Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds. Science Advances, 2021, 7: eabd7851. DOI: 10.1126/sci adv.abd7851

Dong Q, Li X, Wang CZ, Xu SH, Yuan G, Shao W, Liu BD, Zheng Y, Wang HL, Lei XG, Zhang ZQ^#, Zhu B^#. Roles of the CSE1L-mediated nuclear import pathway in epigenetic silencing. Proceedings of the National Academy of Science of the United States of America, 2018, 115: E4013-E4022. DOI: 10.1073/pnas.1800505115

Li X, Shang EC, Dong Q, Li YF, Zhang J, Xu SH, Zhao ZD, Shao W, Lv C, Zheng Y, Wang HL, Lei XG, Zhu B^#, Zhang ZQ^#. Small molecules capable of activating DNA methylation-repressed genes targeted by the p38 mitogen-activated protein kinase pathway. Journal of Biological Chemistry, 2018, 293:7423-7436. DOI: 10.1074/jbc.RA117.000757